Urate Oxidase-Albumin Conjugate Patent Application
Summary
USPTO published patent application US20260091090A1 for a urate oxidase-albumin conjugate invented by seven researchers. The conjugate uses three or more albumins conjugated through a linker to a urate oxidase variant, improving half-life and reducing immunogenicity. The invention addresses prevention and treatment of diseases caused by uric acid, such as gout and hyperuricemia.
What changed
USPTO published patent application US20260091090A1 on April 2, 2026, for a urate oxidase-albumin conjugate characterized by three or more albumins conjugated to a urate oxidase variant through a linker. The application covers the conjugate itself, its preparation method, and the urate oxidase variant component. The technology improves therapeutic half-life and reduces immunogenicity compared to conventional urate oxidase treatments.
This is a standard patent application publication with no compliance requirements. Pharmaceutical companies and drug manufacturers developing uric acid-targeting therapeutics should review the claims to assess potential freedom-to-operate implications or licensing opportunities. The application was filed on October 7, 2025, and contains CPC classifications indicating pharmaceutical compositions (A61K 38/44, A61K 47/545) and enzyme applications (C12N 9/0048).
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF
Application US20260091090A1 Kind: A1 Apr 02, 2026
Inventors
Jeong Haeng Cho, Sun Oh Shin, Hyun Woo Kim, Hyeongseok Kim, Dong Ho Bak, Inchan Kwon, Byungseop Yang
Abstract
The present specification discloses a urate oxidase-albumin conjugate, a preparation method thereof, a urate oxidase variant contained in the urate oxidase-albumin conjugate, and a preparation method thereof. The urate oxidase-albumin conjugate is characterized in that three or more albumins are conjugated to the urate oxidase variant through a linker, thereby improving half-life and reducing immunogenicity. In addition, the urate oxidase-albumin conjugate can be used to prevent or treat various diseases, disorders and/or indications caused by uric acid.
CPC Classifications
A61K 38/44 A61K 47/545 A61K 47/60 A61K 47/643 A61P 19/06 C12N 9/0048 C12Y 107/03003
Filing Date
2025-10-07
Application No.
19351705
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.